Cargando…

ERβ alters the chemosensitivity of luminal breast cancer cells by regulating p53 function

Estrogen receptor α (ERα)-positive breast cancers tend to develop resistance to both endocrine therapy and chemotherapy. Despite recent progress in defining molecular pathways that confer endocrine resistance, the mechanisms that regulate chemotherapy response in luminal tumors remain largely elusiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bado, Igor, Pham, Eric, Soibam, Benjamin, Nikolos, Fotis, Gustafsson, Jan-Åke, Thomas, Christoforos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976481/ https://www.ncbi.nlm.nih.gov/pubmed/29854295 http://dx.doi.org/10.18632/oncotarget.25147

Ejemplares similares

ERβ decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function
por: Bado, Igor, et al.
Publicado: (2016)

Somatic loss of estrogen receptor beta and p53 synergize to induce breast tumorigenesis
por: Bado, Igor, et al.
Publicado: (2017)

ERβ1 represses basal-like breast cancer epithelial to mesenchymal transition by destabilizing EGFR
por: Thomas, Christoforos, et al.
Publicado: (2012)

The ERβ4 variant induces transformation of the normal breast mammary epithelial cell line MCF-10A; the ERβ variants ERβ2 and ERβ5 increase aggressiveness of TNBC by regulation of hypoxic signaling
por: Faria, Michelle, et al.
Publicado: (2018)

Influence of Cellular ERα/ERβ Ratio on the ERα-Agonist Induced Proliferation of Human T47D Breast Cancer Cells
por: Covaleda, Ana M. Sotoca, et al.
Publicado: (2008)

ERβ as a mediator of estrogen signaling in inflammatory breast cancer
por: Nagandla, Harika, et al.
Publicado: (2023)

Expression of TP53 Isoforms p53β or p53γ Enhances Chemosensitivity in TP53(null) Cell Lines
por: Silden, Elisabeth, et al.
Publicado: (2013)

A screening cascade to identify ERβ ligands
por: Filgueira, Carly S., et al.
Publicado: (2014)

ERβ in normal and malignant breast
por: Gustafsson, J-Å, et al.
Publicado: (2005)

Ventral prostate and mammary gland phenotype in mice with complete deletion of the ERβ gene
por: Warner, Margaret, et al.
Publicado: (2020)

Loss of ERβ in Aging LXRαβ Knockout Mice Leads to Colitis
por: Song, Xiaoyu, et al.
Publicado: (2023)

Inhibitory DAMPs in immunogenic cell death and its clinical implications
por: Hayashi, Kazukuni, et al.
Publicado: (2021)

Calcium sensing by the STIM1 ER-luminal domain
por: Gudlur, Aparna, et al.
Publicado: (2018)

ER-luminal [Ca(2+)] regulation of InsP(3) receptor gating mediated by an ER-luminal peripheral Ca(2+)-binding protein
por: Vais, Horia, et al.
Publicado: (2020)

Chemosensitivity and p53; new tricks by an old dog
por: Lønning, Per E, et al.
Publicado: (2012)

Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 are associated with chemosensitivity for breast cancers
por: Yang, Libo, et al.
Publicado: (2019)

TOX3 is expressed in mammary ER(+) epithelial cells and regulates ER target genes in luminal breast cancer
por: Seksenyan, Akop, et al.
Publicado: (2015)

Altering Chemosensitivity by Modulating Translation Elongation
por: Robert, Francis, et al.
Publicado: (2009)

A simple and reproducible prognostic index in luminal ER-positive breast cancers
por: Castellano, I., et al.
Publicado: (2013)

Self-Association of Purified Reconstituted ER Luminal Spacer Climp63
por: Zhao, Jinghua, et al.
Publicado: (2020)

High Mutation Burden in ER-Positive/HER2-Negative/Luminal Breast Cancers
por: Voutsadakis, Ioannis A.
Publicado: (2022)

CAXII Is a Surrogate Marker for Luminal Breast Tumors Regulated by ER and GATA3
por: Porras, Lucas, et al.
Publicado: (2022)

Altered chemosensitivity to CO(2) during exercise
por: Yamashiro, Stanley M., et al.
Publicado: (2021)

Gambogenic acid alters chemosensitivity of breast cancer cells to Adriamycin
por: He, Ye, et al.
Publicado: (2015)

Association of p53 and mitochondrial gene with chemosensitization by metformin in ovarian cancer
por: Wei, De-Hua, et al.
Publicado: (2017)

Chemosensitivity and Endocrine Sensitivity in Clinical Luminal Breast Cancer Patients in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST) Predicted by Molecular Subtyping
por: Whitworth, Pat, et al.
Publicado: (2016)

A mouse model for Luminal epithelial like ER positive subtype of human breast cancer
por: Kumar, MJ Mahesh, et al.
Publicado: (2007)

CCPG1 recognizes endoplasmic reticulum luminal proteins for selective ER-phagy
por: Ishii, Shunsuke, et al.
Publicado: (2023)

An ERβ agonist induces browning of subcutaneous abdominal fat pad in obese female mice
por: Miao, Yi-fei, et al.
Publicado: (2016)

Ahi1 regulates serotonin production by the GR/ERβ/TPH2 pathway involving sexual differences in depressive behaviors
por: Wang, Bin, et al.
Publicado: (2022)

DEPTOR is a direct p53 target that suppresses cell growth and chemosensitivity
por: Cui, Danrui, et al.
Publicado: (2020)

TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer
por: Grote, Isabel, et al.
Publicado: (2021)

p53 Mutation as Plausible Predictor for Endocrine Resistance Therapy in Luminal Breast Cancer
por: Halim, Freda, et al.
Publicado: (2022)

Betulinic acid chemosensitizes breast cancer by triggering ER stress-mediated apoptosis by directly targeting GRP78
por: Cai, Youli, et al.
Publicado: (2018)

TRPS1 modulates chromatin accessibility to regulate estrogen receptor (ER) binding and ER target gene expression in luminal breast cancer cells
por: Scott, Thomas G., et al.
Publicado: (2023)

The therapeutic response of ER+/HER2− breast cancers differs according to the molecular Basal or Luminal subtype
por: Bertucci, François, et al.
Publicado: (2020)

Nitrate-mediated luminal expansion of Salmonella Typhimurium is dependent on the ER stress protein CHOP
por: Sweet, Lydia A., et al.
Publicado: (2023)

Metabolic Actions of Estrogen Receptor Beta (ERβ) are Mediated by a Negative Cross-Talk with PPARγ
por: Foryst-Ludwig, Anna, et al.
Publicado: (2008)

Hes-6, an inhibitor of Hes-1, is regulated by 17β-estradiol and promotes breast cancer cell proliferation
por: Hartman, Johan, et al.
Publicado: (2009)

Reduced menin expression leads to decreased ERα expression and is correlated with the occurrence of human luminal B-like and ER-negative breast cancer subtypes
por: Teinturier, Romain, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_30ne3v9v28mt1ruackeihbl0nj